Translational Studies of JAA-F11: The Reactivity of JAA-F11 with Breast Cancer Cell Lines
Ferguson, Kimiko C.
MetadataShow full item record
The Thomsen-Friedenreich antigen (TF-antigen) is a disaccharide carbohydrate antigen encrypted on normal cells but unmasked and exposed on numerous types of carcinomas such as breast, prostate, bladder, and colon cancer . For this reason, TF-antigen has potential to be used as a marker for treatment of cancers. The JAA-F11 IgG 3 mouse monoclonal antibody shows high specificity for TF-antigen and hence has potential to be used as an agent of immunotherapy of these TF-antigen-positive tumors as they have been shown to extend the life of mice by blocking metastasis. Indirect whole cell EIAs were conducted using JAA-F11 in order to determine which cell lines were TF-positive; with 4T1 mouse breast cancer cell lines serving as the positive and myeloma serving as the negative control. Two human breast cancer cell lines positive for TF-antigen, HCC1397 and T47D as well as the 4T1 cell line were subjected to MTT assays to determine the effect of JAA-F11 on cell proliferation in vitro ; with PNA and an anti-TF antibody A78-G/A7 both serving as controls. As we expected, it was shown that ∼77% of the breast cancer panel tested were TF-antigen-positive; which is close to the 80% of breast carcinomas bearing TF-antigen often reported. Of the triple negative cancers tested in the panel, ∼83% were positive. Both outcomes give promise for the use of JAA-F11 to treat TF-antigen-positive breast cancers. JAA-F11 could be beneficial for triple negative cancers as these have no known targeted treatments. The MTT assays showed that cells proliferation does decrease in the presence of JAA-F11, though significantly only in HCC1397 at 4, 2, and 1μg/ml and in T47D only at 2 and 4μg/ml.